Role of PCSK9 Inhibitors in Diabetes

Stephen Kopecky

New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty…

National Lipid Association

R. Mason

Lp(a): When to Measure it and What to Do About it

Collaborative CME and Research Network

M. O'Donoghue

Updated Lipid Guidelines and Therapy

Complex Coronary Cases

I. Fergus

Role of Coronary Calcification and Risk Stratification

The Texas Heart Institute

E. Hernandez

Recent Cholesterol Guidelines and Integration into Clinical Practice

The North American Thrombosis Forum (NATF)

J. Plutzky, L. Braun, J. Ross

AHA 2022: Cardiovascular Benefit of Lowering LDL Cholesterol Below 4…

AHA 2022 Conference Coverage

N. Marston

Lipids Update: Current Guidelines for Lipid Management

Scripps Health

S. R. Mehta

ACC 2023: Management of Statin Side Effects and How to Keep Them on …

ACC 2023 Conference Coverage

J. Saseen

Cardiology’s Biggest Controversy: The Lumen or the Wall - the Curiou…

Cedars Sinai

J. Forrester

AHA 2022: Long-Term Efficacy and Safety of Inclisiran in Patients Wi…

AHA 2022 Conference Coverage

K. Ray

Directions of Cardiology in the Next Decade: 2022-2032

Houston Methodist DeBakey Heart and Vascular Center

E. Braunwald

How Do I Reverse Coronary Plaque?

Scripps Health

C. J. Suhar

Evaluate the Horrible Cholesterol Lp(a): Prevalence, Impact and Nove…

Scripps Health

N. Lepor

ACC 2022: Updates on Lowering LDL-C in Secondary Prevention - "Go as…

ACC 2022 Conference Coverage

R. Giugliano

Lipid Lowering Therapies: Where Did We Start, Where We Are Now and W…

The Texas Heart Institute

S. Virani

Peripheral Arterial Disease: How To Prevent? When To Diagnose? How T…

Piedmont Heart Institute

A. Klein

I Ordered an Lp(a) Level – Now What?

Collaborative CME and Research Network

M. O'Donoghue

Inside the Studio with Drs. Joseph Rogers and Salim Virani - Current…

The Texas Heart Institute

J. Rogers, S. Virani

Big Questions About Lipoprotein “Little” (a)

MUSC Cardiology

A. Arana Waring